Background: Several thrombelastography functional assays have been developed to guide transfusion in injured patients, but how this acceleration of thrombelastography affects its ability to predict massive transfusion is unknown. The objective of this study is to compare citrated native, citrated kaolin, and citrated rapid thromboelastographies for their prediction of massive transfusion after trauma. We hypothesized that citrated native thrombelastography best predicts massive transfusion. Methods: Data were collected as part of a prospective study of trauma activation patients. All patients received citrated native, citrated kaolin, or citrated rapid thromboelastographies. Logistic regression was used to assess the predictive performance of different thrombelastography assays for massive transfusion.
Rapid TEG efficiently guides hemostatic resuscitation in trauma patients 
t r a c t
Background: Several thrombelastography functional assays have been developed to guide transfusion in injured patients, but how this acceleration of thrombelastography affects its ability to predict massive transfusion is unknown. The objective of this study is to compare citrated native, citrated kaolin, and citrated rapid thromboelastographies for their prediction of massive transfusion after trauma. We hypothesized that citrated native thrombelastography best predicts massive transfusion. Methods: Data were collected as part of a prospective study of trauma activation patients. All patients received citrated native, citrated kaolin, or citrated rapid thromboelastographies. Logistic regression was used to assess the predictive performance of different thrombelastography assays for massive transfusion.
Results: Measurements for all three TEG activating systems was available for 343 patients; 57 (16.6%) required a massive transfusion. Compared to citrated rapid thromboelastographies, citrated kaolin thromboelastographies performed better for activated clotting time/rapid and citrated native thromboelastographies for maximum amplitude and angle. Yet, the 95% confidence intervals overlapped considerably, suggesting the citrated rapid thromboelastographies produced comparable results to the other assays for activated clotting time/reaction time, maximum amplitude, and angle. Conclusion: There was substantial overlap in the performance of the different thrombelastography assays, suggesting citrated rapid thrombelastography is a quick and effective method to guide hemostatic resuscitation in trauma patients and does not perform inferiorly to the citrated native or citrated kaolin thrombelastography despite the addition of activation factors.
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Background
Trauma-induced coagulopathy (TIC) is present in a large proportion (25-35%) of severely injured patients who present to the emergency department and is the leading cause of preventable death after trauma. 1,2 Uncontrolled hemorrhage accounts for up to 40% of deaths in the severely injured hospitalized patients, and half of those deaths occur in the first 2 h after the injury. 3, 4 . Thus, prompt detection of TIC is crucial and has been linked to improved survival in trauma patients. 5 Early detection, however, is limited by the predictive ability of conventional coagulation assays (CCAs), including prothrombin time-international normalized ratio (PT-INR) and partial thromboplastin time (PTT). Consequently, thrombelastography (TEG), a viscoelastic assay that delivers a more comprehensive assessment of homeostatic capacity, has been adopted increasingly for resuscitation of severely injured patients, and the use of TEG in goal-directed hemostatic resuscitation has been shown to dramatically improve survival. 6 Citrated native TEG (CN-TEG) has been well-established for its role in point-of-care resuscitation but poses challenges for clinicians due to the delay in result time (similar to CCAs). This delay of up to 30 min can have detrimental clinical implications. To address this predicament, several functional TEG assays have been developed to decrease the time to available data to guide trans-fusion in trauma and hemorrhage. 7 These assays involve addition of various agonists: kaolin (citrated kaolin TEG; modeling contact activation, or the intrinsic pathway) and tissue factor (citrated rapid TEG; modeling the extrinsic pathway). 8, 9 How this acceleration of TEG affects its efficiency and accuracy is unknown, particularly in its ability to predict need for massive transfusion (MT). This is relevant given the use of TEG in the clinical setting to rapidly guide hemostatic resuscitation. The objective of this study is to compare CN-TEG, citrated kaolin (CK-TEG), and citrated rapid (CR-TEG) TEGs for their prediction of MT after trauma. We hypothesize that CN-TEG (without acceleration from added activators), though requiring more time, best predicts MT.
Patients/methods

Study design
This is an analysis of prospectively collected data from our Trauma Activation Protocol (TAP), a registry that includes all trauma activation patients who sustained blunt or penetrating trauma from 2015 to 2017 at Denver Health Medical Center (DHMC), an American College of Surgeons-verified and Colorado state-certified, academic, level 1 trauma center. The TAP study was approved by the Colorado Multiple Institution Review Board (COMIRB#13-3087) and performed under waiver of consent. Clinical data were collected by trained research professional assistants and included age, sex, mechanism, body mass index (BMI), new injury severity score (NISS), field and hospital arrival systolic blood pressure (SBP), heart rate, Glasgow Coma Scale (GCS), PT-INR, PTT, fibrinogen, and base deficit, as well as the number of units of blood products transfused (red blood cells [RBCs] , frozen plasma]FP24, plasma frozen within 24 h of collection], platelets, and cryoprecipitate) and the volume of crystalloid infused. Traumatic brain injury (TBI) is defined as an abbreviated injury scale (AIS)-head ≥ 3.
Participants
Criteria for inclusion in TAP were adult patients ( ≥ 18 years old) who presented to DHMC as a Trauma Activation, either by ground or air transport from the scene of injury, an emergency department walk-in, or non-transfer patients upgraded to a Trauma Activation on arrival. The criteria were traumatic injury with any of the following: (1) GCS < 8 with presumed thoracic, abdominal, or pelvic injury; (2) respiratory compromise, obstruction, and/or intubation with presumed thoracic, abdominal, or pelvic injury; (3) blunt trauma with SBP < 90 mm Hg; (4) mechanically unstable pelvic injury; (5) penetrating injuries with injury to neck and/or torso with SBP < 90 mm Hg, gunshot wound penetrating the neck/torso, or stab wounds to the neck/torso that require endotracheal intubation; (6) amputation proximal to the ankle or wrist, or (7) the emergency medicine attending or chief surgical resident suspects the patient is likely to require urgent operative intervention. Exclusion criteria included any patient < 18 years, patients whose initial blood sample was not collected within 1 h of injury, infusion of blood products prior to the collection of blood samples, patients presenting as consultations from external hospitals, documented chronic liver disease (total bilirubin > 2.0 mg/dL) or advanced cirrhosis discovered on laparotomy, known inherited defects of coagulation function (eg, hemophilia or Von Willebrand's disease), subsequent downgrades from Trauma Activation to Trauma Alert to non-trauma status in the emergency department, and patients who were pregnant or prisoners. Patients were removed from the study if any of these criteria became known after activation.
Procedures
Whole blood samples were collected at the scene by trained paramedics or on presentation in citrated vacuum tubes (3.5 mL, 3.2% sodium citrate, Greiner Bio-One, Monroe, NC) within 1 h of injury. A team of trained research professional assistants on 24/7 scheduled for prospective studies completed viscoelastic assays within 2 h after blood collection. While TEG assays may have been conducted at slightly different times between patients (though all within 2 h), for each individual patient, their assays were run simultaneously. CN-TEG, CK-TEG, and CR-TEG were performed concomitantly for all patients using the TEG 50 0 0 Thrombelastography Hemostasis Analyzer (Haemonetics, Niles, IL). As described, the functional assays, in contrast to CN-TEG, involve addition of various agonists: kaolin (CK-TEG) and tissue factor (CR-TEG). CN-TEG and CK-TEG yield the following variables: reaction time (R; time elapsed from initiation of test until onset of clot formation, min), angle (rate of clot strength increase, degrees), maximum amplitude (MA; maximal clot strength achieved, millimeters), and percent clot lysis 30 min after reaching MA (LY30, %). The CR-TEG provides the same measurements, except instead of R, CR-TEG provides activated clotting time (ACT; time to beginning of clot formation in seconds). The ACT obtained from CR-TEG is considered comparable to the measurement of R estimated by CN-TEG and CK-TEG. 10,11 R and ACT have been correlated with coagulation factor activity and thrombin generation, the angle with fibrinogen concentration and function, the MA with platelet and fibrin interactions, and LY30 with fibrinolysis. 12 LY30, regardless of assay, due to its multimodal distribution, was expressed as 3 categories as published previously 13 : fibrinolysis shutdown (0-0.8%), physiologic (0.9-2.9%), and hyperfibrinolysis ( ≥ 3%).
The outcome of interest was MT, defined as > 10 units of RBCs transfused in the first 6 h or death within 6 h of presentation. Death within 6 h of presentation was included to account for survivor bias, given some patients may not survive 6 h and/or received > 10 units of RBCs during this time period. MT was triggered if the patient was perceived to have ongoing blood loss and on activation of MT, the blood bank delivered 4 units of type-O, Rh-negative, RBC units and 2 of type-A plasmas (FP24) units. The protocol for MT of blood products has been described previously 12 and includes initial empiric transfusion of FFP:RBC 1:2. MT was stopped as clinically indicated once control of bleeding was achieved and/or the patient was hemodynamically stable.
Statistical analysis
Statistical analyses were performed using SAS for Windows version 9.4 (SAS Institute, Cary, NC), and power calculations were conducted using PASS 14 Power Analysis and Sample Size Software 2015 (NCSS, LLC. Kaysville, UT). Categorical variables were compared using chi-square or Fisher Exact test as appropriate. Continuous variables were expressed as median values (interquartile range, IQR) and compared using the Wilcoxon test. The predictive performance of the different assays for MT was assessed using the area under the receiver operating characteristics curve (AUROC). The AUROCs for the TEG assays were compared using the DeLong et al test. 14 To assess the predictive performance of LY30, we compared its sensitivity, specificity, positive predictive value, and negative predictive value for MT. All tests were 2-tailed and significance established at P < .05.
Results
From 2015 to 2017, 611 patients were enrolled in the TAP study, but only 343 patients had data for all 3 TEGs (CN-, CK-, and CR-TEG; Table I , Fig. 2 ) . The majority of patients were male (78.7%), and the median age was 32.0 years (IQR 25.6-45.8). Approximately half of the patients presented after blunt trauma, and the median NISS was 18 (IQR 6-34). Overall, 41.4% of the patients required RBC transfusion during the first 6 h and 16.6% of patients ultimately required MT. The median ACT in CR-TEG was the same among the MT and non-MT patients (121 s; P = 0.274). With CK-TEG and CN-TEG, the median R time was approximately 1 min greater in the MT group versus non-MT group ( P < .0 0 01 and .0 020, respectively). Compared to CR-TEG and CN-TEG, CK-TEG performed better for ACT/R ( P = .0038) with an area under the curve (AUC) of 0.703, compared to 0.598 for CR-TEG ACT and 0.643 for CN-TEG R. The median angle was less in the MT group versus non-massive transfusion group on all 3 TEGs. Compared to CR-TEG and CK-TEG, CN-TEG did not perform better for angle, with an AUC of CN-TEG of 0.763 compared to 0.765 for CK-TEG and 0.686 for CR-TEG ( P = .3323). The median MA was also less in the MT group, compared to the non-MT group, in all 3 TEGs. Compared to CR-TEG and CK-TEG, CN-TEG tended to perform better for MA with an AUC of 0.827 compared to 0.798 for CK-TEG and 0.796 for CR-TEG ( P = .0766).
CK-TEG was the only assay with a statistically significant superior performance for ACT-R, while there was no statistically significant difference between the assays for angle or MA. On further examination, the 95% confidence intervals overlapped considerably ( Table II ) , suggesting the CR-TEG produces comparable results to the other functional assay for ACT, MA, and angle. When all TEG measurements for each assay (CR-, CN-, CK-TEG) were in the model (ACT/R + MA + angle) on logistic regression, there was no difference in predictive performance compared to CR-TEG ( P = .5300), and the majority of AUCs were > 0.6 for all assays ( Fig. 1 ) .
LY30 > 3% had a low positive predictive value for MT in all 3 TEG assays, but CK-TEG LY30 had the greatest negative predictive value of MT of 93.7% (compared to 93.4% in CN-TEG LY30 and 92.0% in CR-TEG LY30). The current sample allowed us to detect 0.07 to 0.08 points difference between the AUROCs with 95% confidence and 80% power, assuming, based on preliminary data, that the reference group had AUROCs from 0.65 to 0.80 and the correlation between tests was high with Spearman Rho = 0.80 to 0.70 (MA, LY30). For lesser correlations (ACT/R, angle), with Spearman Rho = 0.45 to 0.65, the sample allowed for the detection of differences of 0.13 to 0.14.
Discussion
The objective of this study is to compare CN-TEG, CK-TEG, and CR-TEG for their prediction of MT after trauma. The role of TEG in point-of-care based resuscitation in trauma has been well validated 6, 15 and, thus, adoption of TEG-guided resuscitation has become more widespread, with a recent report indicating that 23% of American College of Surgeons Trauma Quality Improvement Program (ACS-TQIOP) level 1 hospitals incorporate TEG into their MT protocol and strategy. 16 A number of prospective studies have described lesser mortality and death from exsanguination when TEGguided resuscitation is employed 17 and have demonstrated superiority of TEG compared to CCAs for predicting transfusion requirement. 18 Our group reported a randomized control trial in which patients were randomized to CCA-guided resuscitation versus citrated rapid TEG-guided resuscitation and demonstrated improved 28-day survival in the latter group. 6 Over time, a number of TEG assays have been developed to not only expedite the time to results but to better characterize specific hemostatic parameters. The CK-TEG involves clot initiation by addition of activating solution consisting of kaolin (a mineral clay, hydrated aluminum silicate, which activates factor XII), phospholipids, and buffered stabilizers. This assay simulates the intrinsic pathway of coagulation. Interpretation of these results needs to be performed with a degree of clinical skepticism, however, because some data with CK-TEGs have described a pattern of secondary fibrinolysis that does not correlate with the clinical picture of a patient nor the hematologic markers of fibrinolysis. This pattern may suggest that this observed lysis is caused by platelet-mediated hyper-retraction or a pathway involving factor XII, kallikrein, bradykinin, and consequent fibrinolysis. 19 Furthermore, evidence suggests that the kaolin pathway can also have multiple effects on platelets, such as release of platelet factor 3 and cytoskeletal structure related to clot retraction, confounding the analysis of MA and lysis. 20 In contrast to CK-TEG, the extrinsic pathway of coagulation is simulated through the CR-TEG. This assay involves addition of kaolin and tissue factor (cell surface glycoprotein that binds to coagulation factor VII), causing a thrombin burst and even more rapid results. This assay can provide early results (ACT, K) within 6 min and later results (angle, MA) within 15 min. This compares to at least 20 min for kaolin TEGs and 30 min for native TEG and CCAs. 15, 21 In general, these "activated" assays (CR-TEG, CK-TEG) cause a shortening of the reaction time (representing fibrin formation) and kappa value (time interval from R to where fibrin cross-linking provides a pre-defined resistance), as well as an increase in angle (rate at which clot strengthens), and maximum amplitude (maximal clot strength). Criticism of these accelerated assays is that they can mask coagulation abnormalities, particularly because the CR-TEG causes such a rapid, massive thrombin burst. For this reason, CN-TEG, for example, remains relevant for use in research due to its ability to dampen false signals.
The role of various TEG assays in predicting MT has not been investigated in a comparative fashion between CN-, CK-, and CR-TEG. Thus, this study contributes to a gap in the literature on TEGbased resuscitation of MT patients. In this study, our hypothesis that CN-TEG without the addition of activators would have the best predictive value for MT, was not supported. Rather, the results indicate that despite the ability of activators to potentially mask coagulation aberrancies, CR-TEG is not an inferior method to guide MT in patients compared to CN-or CK-TEG. While ACT/R is relatively weak in all assays, angle and MA correlate well with MT requirement. This is particularly beneficial knowledge, given the rapidity of results of CR-TEG in the setting of active resuscitation of an unstable trauma patient. The only other existing studies comparable to ours include 2 observational studies of 182 and 404 trauma patients respectively, in which the predictive ability of early amplitude (at 5 and 10 min) of CR-TEG and CK-TEG for transfusion and mortality was compared. 22, 23 CR-TEG predicted mortality in transfused patients, while CK-TEG did not in one study 22 , and CR-TEG had the strongest correlation between its early amplitude and massive transfusion in both studies. 23 The reported data support these studies and other existing literature, which describe CR-TEG's predictive ability for transfusion and MT. In a study of 272 severely injured patients at a level 1 trauma center, CR-TEG ACT, R, and MA predicted transfusion of RBCs within the first hour of arrival, and all CR-TEG measurements predicted transfusion of RBCs within the first 2 h. 15 The LY30 from the CR-TEG has also been shown to correlate with MT and mortality at 24 h and 30 d, though this correlation is not as strongly indicated in our study (AUC 0.527) 24 . CK-TEG has also been demonstrated in other studies to have similar prediction of MT compared to CR-TEG, albeit with a greater time to results. On examining a total of 182 trauma patients from a level 1 trauma center, Johansson et al found that MA, G and LY30 from both CK-TEG and CR-TEG were both predictors of MT. 17 Limitations to these data include that though blood was drawn at roughly equivalent time points for patients, TEGs were conducted at various durations of time from venipuncture; however, the TEGs were all conducted within 2 h of venipuncture, and the various assays were conducted at the same time for each patient. Another limitation is the use of ROC analysis for LY30, because ROC analysis typically assumes a binomial distribution; however, it has been observed that LY30 plotted against mortality instead has a more inverse parabolic relationship 13 , which may explain why we did not see greater AUCs or predictive abilities among the TEG assays.
In conclusion, contrary to what was expected, there was a significant overlap in the performance of the different TEG assays, suggesting CR-TEG is an effective method to guide hemostatic resuscitation in trauma patients; also the CR-TEG lacked superiority to CN-and CK-TEGs, despite addition of activation factors. LY30 > 3% demonstrated utility for prediction of MT with a high nega-tive predictive value in all assays. The thresholds based on CR-TEG for TEG-guided resuscitation with ROC curve analysis revealed the strongest ROC prediction for angle (0.80 AUC) and MA (0.81 AUC). 6 The presented data suggest these thresholds can be utilized with confidence without concern for masking coagulation abnormalities by using an activated TEG. 25 
